It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

1 **Comparison of haemoglobin concentration measurements using HemoCue-301 and**

2 **Sysmex XN-Series 1500: a survey among anaemic Gambian infants aged 6-12 months**

- 3
- 4 Mamadou Bah, MSc^{1,2}, Hans Verhoef, PhD², Abdou Camara¹, SEN, Morris Nden Ngom¹,
- 5 SEN, Demba Jallow¹, SEN, Kebba Bajo¹, Foday Bah¹, Maarten Pleij² BSc, Maaike Klappe²
- 6 BSc, Alasana Saidykhan¹, BSc, Emmanuel Okoh, MBBS, MPH¹, Abdoulie Bah, BSc¹, Carla
- 7 Cerami, MD, PhD¹ ***
- 8
- 9 *¹Medical Research Council (MRC) Unit The Gambia at London School of Hygiene & Tropical*
- 10 *Medicine (LSHTM), PO Box 273, Fajara, The Gambia*
- 11 *²Division of Human Nutrition and Health, Wageningen University, PO Box 17, 6700 AA*
- 12 *Wageningen, The Netherlands*
- 13 **Correspondence to: Dr Carla Cerami at the MRC Unit The Gambia @ LSHTM, Atlantic*
- 14 *Boulevard, Fajara, Banjul, The Gambia Email: carla.cerami@lshtm.ac.uk; Tel: +220-*
- 15 *7875756*

16 **ABSTRACT**

17 **Background & Aims:** In low-income countries, point-of-care photometers are used in the 18 screening and management of anaemia in individuals, but also in the assessment of 19 population iron status when evaluating efficacy of intervention studies or public health 20 interventions. We aimed to evaluate the accuracy of a commonly used photometer, 21 HemoCue-301, in determining haemoglobin concentration among anaemic children aged 6- 22 12 months in a field setting in rural Africa.

23 **Methods:** This report concerns a secondary analysis of data from Gambian infants being 24 screened for an ongoing randomized controlled trial. In those found to be anaemic by 25 HemoCue-301, haemoglobin concentration was measured by Sysmex XN-1500, an 26 automated haematology analyser that was used as a reference. Passing-Bablok regression 27 analysis was used to estimate the regression constant (systematic deviation between two 28 measurement methods that remain consistent across the range of measurements) and 29 proportional bias (systematic deviation between two measurement methods that change in 30 magnitude relative to the value being measured).

31 **Results:** Analysis was based on 227 participants. There was strong evidence of absolute 32 bias among moderately anaemic participants (haemoglobin concentration at 8.0g/dL) 33 (absolute bias: 1.12g/dL; 95% CI: 0.91 to 1.37g/dL; proportional bias: 14.0%; 95% CI: 11.4% 34 to 17.1%) in haemoglobin concentrations measured by HemoCue-301 compared to those 35 measured by Sysmex XN-Series1500. Bias was marginal at haemoglobin concentration of 36 11.0g/dL (absolute bias: -0.08g/dL; 95% CI: -0.18 to 0.07g/dL; proportional bias: -7.3%; 95% 37 CI: -6.5% to 0.6%).

38 **Conclusion:** Haemoglobin measurements by HemoCue-301 seem substantially biased in 39 participants with haemoglobin less than 8.0g/dL.

40 **Key words:** Diagnostic techniques, haematologic; haemoglobin, anaemia; point-of-care 41 systems; child; Gambia

42 **1. INTRODUCTION**

43 Accurate measurement of haemoglobin concentrations is important in the screening and 44 management of anaemia in individuals, but also in the assessment of population iron status 45 in surveys to evaluate the efficacy of intervention studies or public health interventions. 46 Automated haematology analysers are generally considered the reference standard. These 47 analysers are expensive and require specific ambient temperatures, cold storage for 48 reagents, and a stable source of electricity, which poses challenges in field settings (1). To 49 address these challenges, various battery-operated point-of-care photometers have been 50 introduced. They rely on either pooled or single capillary blood samples, making them 51 convenient for use in field settings and are widely used for country-wide anaemia prevalence 52 studies (2).

53

54 One such photometer is the HemoCue-301 (HemoCue, Ängelholm, Sweden), which was 55 specifically developed to withstand challenging environments and does not utilise any 56 hygroscopic ingredients (3). The HemoCue-301 utilises a double-wavelength method, 57 measuring the absorbance of whole blood at 506nm the Hb/HbO2 isosbestic point (i.e., the 58 wavelength where Hb and HbO2 have the same absorbance or intensity), and at a 59 wavelength of 880nm to compensate for turbidity. However, this technique is sensitive to 60 oxygen, resulting in a 1.3% increase in measured haemoglobin concentration per minute 61 the sample is left in open air (4). Therefore, readings must be completed within 20-30 62 seconds to ensure accuracy (3).

63

64 Despite their benefits, variability in haemoglobin measurements between these point-of-care 65 devices and automated haematology analysers has been reported (5). A systematic review 66 of 8 studies revealed higher haemoglobin concentration measurements of capillary blood 67 using HemoCue-301 compared to measurement of venous blood in automated haematology

68 analysers (4), with differences ranging from 0.5 to 6.1 g/L (4). However, most of these 69 studies determined the difference in haemoglobin measurement between the techniques 70 using Bland-Altman analysis (6–14). Unlike Bland-Altman analysis, Passing-Bablok 71 regression analysis is a non-parametric method that does not assume constant 72 measurement errors between methods and is robust against outliers (15).

73

74 We aimed to evaluate the accuracy of the HemoCue-301 in determining haemoglobin 75 concentration among anaemic children aged 6-12 months in a field setting in rural Africa. As 76 a reference, we used the Sysmex XN-1500 (Sysmex Corporation, Kobe, Japan), an 77 automated haematology analyser that utilises a cyanide-free sodium lauryl sulphate reagent 78 to lyse red blood cells, which, once released, forms a stable-coloured complex that is then 79 measured photometrically (16).

80

81 **2. Materials & Methods**

82 This study contains an analysis of baseline data obtained from an ongoing efficacy trial of 83 haem iron versus ferrous sulphate in infants aged 6-12 months (17). The trial received 84 ethical approval from the Scientific Coordinating Committee of the Medical Research 85 Council (MRC) Unit The Gambia, the Joint Gambia Government MRC Ethics Committee, 86 and the Ethics Committee at the London School of Hygiene and Tropical Medicine 87 (LEO27648) and adheres to the principles of Good Clinical Practice, with oversight from a 88 Data Safety and Monitoring Board, and will be subject to monitoring by the Clinical Trials 89 Office at the MRCG@LSHTM. The trial is registered with the Pan African Clinical Trial 90 Registry (PACTR202210523178727) at www.pactr.org.

91

92 *2.1 Sample collection*

93 Enrolment of participants started on the 11th of May 2023 in Jara West and Kiang East of 94 The Gambian and concluded on the 1st of November 2023. Potential participants were 95 recruited from vaccination clinics or in their respective communities. After obtaining consent 96 from parents/guardians, capillary blood samples were collected in the field by a trained 97 nurse. While seated, the participant's finger was cleaned, and non-fasting blood was 98 collected by pricking the thumb with a lancet (Microtainer Contact-Activated Lancet, Becton-99 Dickinson, Franklin Lakes, NJ, USA). The initial capillary droplet was removed, and the 100 second droplet was used to fill the microcuvette, ensuring that no air bubbles were 101 introduced. Any excess blood on the sides of the microcuvette was wiped, and haemoglobin 102 concentration was measured immediately by inserting the microcuvette into the HemoCue-103 301 photometer. Children with anaemia (haemoglobin <11.0g/dL by HemoCue-301) were 104 invited for further screening and haemoglobin assessment was repeated using the reference 105 method. For each participant, a 0.5mL venous blood sample was collected by a nurse into 106 $K₂EDTA$ tubes (BD microtainer, reference number 365975), and samples were kept 107 between 4°C–8°C until transferred to a central laboratory, where haemoglobin concentration 108 was assessed within 4 hours of initial blood draw using a Sysmex XN-1500 analyser. Study 109 data were collected and managed using REDCap electronic data capture tools hosted at 110 MRC Unit The Gambia (18).

111

112 *2.2 Quality control*

113 The HemoCue-301 is factory-calibrated against international reference samples and no 114 further calibration is possible by the end user (19). Weekly quality control checks were done 115 for the HemoCue-301 utilising the control blood samples purchased for use with the Sysmex 116 machine (XN Check, L1 catalogue number; 213484, L2 catalogue number; 213485, L3 117 catalogue number; 213486). No quality control failures were noted during the trial. The 118 Sysmex XN-Series 1500 (Sysmex Corporation, Japan) instrument is housed in an

119 accredited Good Clinical Laboratory Practice (GCLP) laboratory at MRCG at LSHTM at the 120 Keneba field station. Daily quality checks and controls were conducted. All sample analyses 121 were carried out by a trained scientific officer to ensure the accuracy and reliability of the 122 data throughout the study.

123

124 *2.3 Statistical analysis*

125 The statistical analysis was conducted in RStudio version 3.0. Passing-Bablok regression, 126 a non-parametric method, was used to determine potential absolute and proportional bias 127 using the Method Comparison Regression (mcr) package. Bias refers to non-random errors 128 between measurements obtained from two different methods. Proportional bias refers to a 129 systematic error in which the magnitude of the bias is directly proportional to the true value 130 of the variable being measured. Unlike traditional linear regression, the Passing-Bablok 131 regression method is insensitive to outliers and does not assume normal distribution, 132 constant variance, or a linear relationship (15). We defined absolute and proportional bias 133 when the confidence intervals excluded 0 and 1 for the intercept or the slope respectively. 134 A difference of ±7% between methods as recommended by the College of American 135 Pathologists and the Westgard Clinical Laboratory Improvement Amendments was 136 considered acceptable (20).

137

138 **3. RESULTS**

139 A total of 227 participants had their haemoglobin assessed using both the HemoCue-301 140 and Sysmex XN-Series 1500 and were included in the analysis. The participants had a mean 141 age of 7.5 months (SD: 1.6 months); 52% were female. Of 227 participants identified as 142 anaemic according to the HemoCue-301, 17 were found to be not anaemic using the 143 Sysmex haematology analyser. One participant was classified as severely anaemic

144 (haemoglobin <7.0 g/dl) according to the Sysmex haematology analyser but not the 145 HemoCue-301.

146

147 The median haemoglobin concentrations for HemoCue-301 and Sysmex XN-Series were 148 10.2 g/dL (IQR: 9.8, 10.7 g/dL) and 9.8 g/dL (IQR:9.2, 10.4 g/dL), respectively. For severe 149 anaemia (haemoglobin concentration at 6.5 g/dL), Hemocue measurements showed an 150 absolute bias of 1.72 g/dL (95% CI: 1.37 to 2.10 g/dL) and a proportional bias of 26.5% (95% 151 CI: 21.1% to 32.3%). Moderate anaemia (haemoglobin concentration at 8.0 g/dL) showed 152 an absolute bias of 1.12 g/dL (95% CI: 0.91 to 1.37 g/dL) and a proportional bias of 14.0% 153 (95% CI: 11.4% to 17.1%), while mild anaemia cases (haemoglobin concentration <10.0 154 g/dL) showed an absolute bias of 0.32 g/dL (95% CI: 0.26 to 0.42 g/dL) and a proportional 155 bias of 3.2% (95% CI: 2.6% to 4.2%). Bias was marginal at haemoglobin concentration of 156 11.0 g/dL (absolute bias: -0.08 g/dL; 95% CI: -0.18 to 0.07; proportional bias: -7.3%; 95% 157 CI: -6.5 to 0.6). A modest positive correlation coefficient of 0.31, as indicated by Kendall's 158 tau, indicates limited agreement between the measurement methods.

159

160 **4. DISCUSSION**

161 We demonstrated that haemoglobin measurements between HemoCue-301 and the 162 Sysmex XN-1500 vary across different haemoglobin concentrations and the magnitude of 163 bias is inversely proportional to haemoglobin concentration. There was strong evidence of 164 a absolute bias in haemoglobin concentrations above the acceptable difference of $\pm 7\%$ set 165 by the College of American Pathologists and Westgard Clinical Laboratory Improvement 166 Amendments in moderate and severly anaemic participants (20).

167

168 The diagnostic accuracy of HemoCue-301 compared to automated hematology analyzers 169 has been examined in several studies. While some studies have reported acceptable

170 differences within ±7%, others have shown higher difference(4,21). Our study indicated that 171 HemoCue-301 measurements were 26.5% higher than the Sysmex values at a hemoglobin 172 concentration of 6.5 g/dL with an absolute bias of 1.72 g/dL much higher than the acceptable 173 ±7%. Among participants with a hemoglobin concentration of 8.0 g/dL, 14.0% showed an 174 absolute bias of 1.12 g/dL, while those with a hemoglobin concentration of 11.0 g/dL showed 175 marginal or non-existent bias. Similarly, a study conducted in Laotian children reported a 176 higher bias in anaemic compared to non-anaemic children (22). In blood donors, no bias 177 was observed at a haemoglobin concentration of 12.0 g/dl when compared to the WHO 178 reference standard haemoglobin-cyanide technique (11). A systematic review of 8 studies 179 among adults indicated higher HemoCue-301 haemoglobin concentration measurements 180 compared to automated analysers. This study concluded that the difference fell within the 181 acceptable limit of ±7% set by the College of American Pathologists and Westgard Clinical 182 Laboratory Improvement Amendments (4). However, it is important to acknowledge that 183 differences in haemoglobin measurements vary between methods at different 184 concentrations, as demonstrated by our study, which was not accounted for in this study.

185

186 The HemoCue-301 operates on spectrophotometric principles, where the absorbance of 187 light passing through a blood sample is directly proportional to the concentration of 188 haemoglobin at the Hb/HbO2 isosbestic point. Due to the stringent adherence to the 189 haemoglobin measurement protocol within our clinical trial, the observed higher 190 haemoglobin concentrations, particularly in anaemic children, are likely attributable to device 191 bias arising from increased absorbance at lower haemoglobin concentrations rather than 192 preanalytical errors. In contrast, a study among women in Peru has indicated lower 193 haemoglobin concentrations measured by HemoCue-301 compared to automated 194 analysers, with 50% of these women classified as anaemic according to HemoCue-301 (23). 195 However, in our analysis, only 7.4% of participants were misclassified as anaemic by the

196 HemoCue-301, while they were classified as normal (haemoglobin concentrations greater 197 than 11 g/dL) according to the Sysmex XN-1500.

198

199 According to WHO guidelines, paediatric blood transfusion should be performed on patients 200 with haemoglobin less than 4.0 g/dl with clinical signs of severity (24). However, few facilities 201 in sub-Saharan countries have access to reliable haemoglobin tests with a turnaround time 202 between 1 and 8 hours [5] As a result, around 40-65% of requested transfusions are based 203 on clinical judgment, such as severe pallor (5). This clinical judgment is often inaccurate in 204 identifying severe anaemia (haemoglobin less than 5.0 g/dl), leading to unnecessary 205 transfusions (25,26). This does not only expose children to transfusion-related risks but may 206 also contribute to blood scarcity for patients who are most in need (26,27). Therefore, the 207 ability to provide rapid diagnosis of severe anaemia is critical for life-saving interventions 208 and the prioritisation of blood units for those in most need. A study conducted in Kenya, 209 Tanzania, and Uganda revealed that a delay in blood transfusion for severely anaemic 210 children within the first 8 hours resulted in a 52% mortality rate, with 90% of these deaths 211 occurring within the initial 2.5 hours(28). This outcome was associated with insufficient blood 212 units, emphasising the importance of managing and prioritising the already scarce blood 213 resources to prevent avoidable deaths (28). Conversely, in a Kenyan hospital, children 214 receiving transfusion on the same day, compared to the following day, were associated with 215 a 42% reduction in mortality (29). In the TRACT trial, where participants aged between 2 to 216 12 months were randomised to either immediate or triggered transfusion, active hemoglobin 217 measurement by the HemoCue-301 method in the control group resulted in 49.0% of 218 children receiving timely transfusions. Additionally, there was evidence of lower mortality, 219 perhaps due to the active hemoglobin monitoring every 8 hours in the first 24 hours and at 220 48 hours (30). However, our study showed that this method tends to overestimate

221 hemoglobin concentration, particularly in participants with moderate to severe anaemia, 222 potentially resulting in children who require a blood transfusion not receiving it.

223

224 The WHO is currently involved in ongoing research to comprehensively understand 225 preanalytical and analytical factors influencing haemoglobin measurement using these 226 point-of-care devices. This research aims to inform the development of new guidelines in 227 this area (31) and our study will contribute to the existing evidence that can be utilised in 228 these guidelines' development. This study is part of an ongoing clinical trial, thus ensuring 229 stringent monitoring and adherence to trial protocols throughout the blood sampling process 230 and haemoglobin measurements. This study has several limitations as it was a secondary 231 data analysis using a convenience sampling method. Consequently, the findings may not 232 be generalisable to rural Gambian children aged between 6 and 12 months. Additionally, 233 capillary and venous blood sampling for haemoglobin measurement were not performed on 234 the same day. The retrospective nature of our study limited our ability to explore the potential 235 impact of different blood sample types (venous vs capillary) on haemoglobin concentration 236 measurements. Furthermore, our study design did not allow for a direct comparison between 237 point-of-care tests and automated haematology analysers regarding anaemia prevalence. 238 This is because only children identified as anaemic by HemoCue-301 underwent 239 haemoglobin measurements using the automated analyser.

240

241 **5. Conclusion**

242 Our study indicated that bias due to HemoCue-301 depends on the actual Hb concentration, 243 and seems unacceptably high at Hb values below 8.0 g/dL. While this method may offer 244 convenience in field surveys for estimating anaemia prevalence, caution is required when 245 using it for a screen-and-treat approach.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.05.24313093;](https://doi.org/10.1101/2024.09.05.24313093) this version posted September 6, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

247

248 **Declarations**

249 *Acknowledgements*

250 We thank the IDeA3 study team at MRCG@LSHTM for their dedicated support, the MRCG 251 Keneba laboratory, the data management team and the MRCG Clinical Trial Unit. We also 252 thank the participants and communities of Kiang East and Jarra West.

253

254 *Authors' contributions*

255 MB conceived this paper, and contributed to the analysis, writing of the original paper, 256 reviewing, and editing and coordinated the study as part of his PhD, overseeing all aspects 257 of study implementation. CC conceived the overall trial idea and acquisition of funding, and 258 design and is the overall principal investigator, contributed to the writing of the paper, 259 reviewing, editing and supervising MB. HV contributed to the study design, sample size 260 calculation and statistical analysis plan, writing of the paper, reviewing, and editing and co-261 supervised MB. AMP contributed to the study idea, design, writing of the paper, reviewing, 262 and editing. EO is the research clinician on the trial contributed to data collection and 263 reviewed and edited the paper. AC, MNG, DJ, KB, AS, MK, and MP contributed to data 264 collection reviewing and editing of the paper. AB is the data manager and contributed to the 265 reviewing and editing of the paper.

266

267 *Funding*

268 This study was funded by a grant from the UK Research & Innovation (UKRI) to the Medical 269 Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine (grant 270 reference: MR/R023360/1). CC, AMP, EO, AB, AC, MNG, DJ, KB and AS are funded 271 through MRCG@LSHTM. MB is partially funded through MRCG@LSHTM, Wageningen 272 University and MR/R023360/1. HV, MK, and MP are funded by Wageningen University.

273

- 274 *Role of the funding source*
- 275 The funder had no role in the design or implementation of the study.

- 277 *Competing interests*
- 278 There is no competing interest to disclose.
- 279
- 280 *Authors and Affiliations*
- 281 Mr. Mamadou Bah (PhD Candidate and Sub-Investigator, Affiliation: MRC Unit The Gambia
- 282 @ LSHTM & Wageningen University, Division of Human Nutrition and Health, The
- 283 Netherlands)
- 284 Dr. Carla Cerami (Principal Investigator and Research Group Lead: Iron, Infection and 285 Anaemia; Affiliation: MRC Unit The Gambia @ LSHTM Research Group)
- 286 Prof. Andrew M Prentice (Sub-Investigator, Nutrition and Planetary Health Theme Leader;
- 287 Affiliation: MRC Unit The Gambia @ LSHTM)
- 288 Dr. Hans Verhoef (Sub-Investigator and Trial Statistician, Affiliation: Wageningen University,
- 289 Division of Human Nutrition and Health, The Netherlands)
- 290 Dr Emmanuel Okoh (Research Clinician: MRC Unit The Gambia @ LSHTM Research 291 Group)
- 292 Abdoulie Bah, (Data support assistant: MRC Unit The Gambia @ LSHTM Research Group)
- 293 Alasana Saidykhan, (Scientific Officer: MRC Unit The Gambia @ LSHTM Research Group)
- 294 Abdou Camara, (Nurse Coordinator: MRC Unit The Gambia @ LSHTM Research Group)
- 295 Kebba Bajo, (Field Coordinator: MRC Unit The Gambia @ LSHTM Research Group)
- 296 Morris Ndene Ngom, (Research Nurse: MRC Unit The Gambia @ LSHTM Research Group)
- 297 Demba Jallow, (Research Nurse: MRC Unit The Gambia @ LSHTM Research Group)
- 298 Foday Bah, (Field Suppervisor: MRC Unit The Gambia @ LSHTM Research Group)

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.05.24313093;](https://doi.org/10.1101/2024.09.05.24313093) this version posted September 6, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

- 299 Maaike Klappe (MSc student, Affiliation: Wageningen University, Division of Human
- 300 Nutrition and Health, The Netherlands)
- 301 Maarten Pleij (MSc student, Affiliation: Wageningen University, Division of Human Nutrition
- 302 and Health, The Netherlands)
- 303
- 304
- 305

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

306 **References**

307

313

316

318

328

334

342

347

- 308 1. Garcia-Casal MN, Dary O, Jefferds ME, Pasricha SR. Diagnosing anemia: 309 Challenges selecting methods, addressing underlying causes, and implementing 310 actions at the public health level. Ann N Y Acad Sci [Internet]. 2023 Jun 1 [cited 311 2023 Nov 21];1524(1):37–50. Available from:
- 312 https://onlinelibrary.wiley.com/doi/full/10.1111/nyas.14996
- 314 2. Srivastava T, Negandhi H, Neogi SB, Sharma J, Saxena R. Methods for Hemoglobin 315 Estimation: A Review of "What Works. J Hematol Transfus. 2014;2(3):1028.
- 317 3. HemoCue. HemoCue ® Hb 301. 2024.
- 319 4. Whitehead RD, Mei Z, Mapango C, Jefferds MED. Methods and analyzers for 320 hemoglobin measurement in clinical laboratories and field settings. Ann N Y Acad 321 Sci [Internet]. 2019 [cited 2024 Jan 30];1450(1):147. Available from: 322 /pmc/articles/PMC6709845/ 323
- 324 5. Uyoga S, George EC, Bates I, Olupot-Olupot P, Chimalizeni Y, Molyneux EM, et al. 325 Point-of-care haemoglobin testing in African hospitals: a neglected essential 326 diagnostic test. [cited 2023 Nov 21]; Available from: 327 www.ekfdiagnostics.com/diaspect.html
- 329 6. Jaggernath M, Naicker R, Madurai S, Brockman MA, Ndung'u T, Gelderblom HC. 330 Diagnostic Accuracy of the HemoCue Hb 301, STAT-Site MHgb and URIT-12 Point-331 of-Care Hemoglobin Meters in a Central Laboratory and a Community Based Clinic 332 in Durban, South Africa. PLoS One [Internet]. 2016 Apr 1 [cited 2023 Nov 21];11(4). 333 Available from: https://pubmed.ncbi.nlm.nih.gov/27046200/
- 335 7. Lardi AM, Hirst C, Mortimer AJ, McCollum CN. Evaluation of the HemoCue® for 336 measuring intra-operative haemoglobin concentrations: A comparison with the 337 Coulter Max-M®. Anaesthesia. 1998;53(4):349–52. 338
- 339 8. Rechner IJ, Twigg A, Davies AF, Imong S. Evaluation of the HemoCue compared 340 with the Coulter STKS for measurement of neonatal haemoglobin. Arch Dis Child 341 Fetal Neonatal Ed. 2002;86(3).
- 343 9. Karakochuk CD, Janmohamed A, Whitfield KC, Barr SI, Vercauteren SM, Kroeun H, 344 et al. Evaluation of two methods to measure hemoglobin concentration among 345 women with genetic hemoglobin disorders in Cambodia: A method-comparison 346 study. Clinica Chimica Acta. 2015 Feb 20;441:148–55.
- 348 10. Morris SS, Ruel MT, Cohen RJ, Dewey KG, De La Brière B, Hassan MN. Precision, 349 accuracy, and reliability of hemoglobin assessment with use of capillary blood. Am J 350 Clin Nutr. 1999 Jun 1;69(6):1243–8.
- 352 11. Morris LD, Osei-Bimpong A, McKeown D, Roper D, Lewis SM. Evaluation of the 353 utility of the HemoCue 301 haemoglobinometer for blood donor screening. Vox 354 Sang. 2007 Jul;93(1):64–9.
- 355

- 356 12. Karakochuk CD, Hess SY, Moorthy D, Namaste S, Parker ME, Rappaport AI, et al. 357 Measurement and interpretation of hemoglobin concentration in clinical and field 358 settings: a narrative review. Ann N Y Acad Sci [Internet]. 2019 Aug 1 [cited 2023 359 Dec 4];1450(1):126–46. Available from: 360 https://onlinelibrary.wiley.com/doi/full/10.1111/nyas.14003
- 362 13. Getaneh Z, Woldu B, Sitotaw C, Melku M. Comparison of hemoglobin levels by 363 HemoCue301+ and Sysmex KX-21N at University of Gondar Hospital, Northwest 364 Ethiopia, 2020. Clin Lab [Internet]. 2022 [cited 2023 Dec 4];68(11):2316–24. 365 Available from: https://pubmed.ncbi.nlm.nih.gov/36378003/

361

366

371

375

380

384

390

394

398

- 367 14. Jain A, Chowdhury N. Comparison of the accuracy of capillary hemoglobin 368 estimation and venous hemoglobin estimation by two models of HemoCue against 369 automated cell counter hemoglobin measurement. Asian J Transfus Sci [Internet]. 370 2020 Jan 1 [cited 2023 Dec 4];14(1):49. Available from: /pmc/articles/PMC7607980/
- 372 15. Bilić-Zulle L. Comparison of methods: Passing and Bablok regression. Biochem Med 373 (Zagreb) [Internet]. 2011 [cited 2023 Dec 5];21(1):49–52. Available from: 374 https://pubmed.ncbi.nlm.nih.gov/22141206/
- 376 16. Hill VL, Simpson VZ, Higgins JM, Hu Z, Stevens RA, Metcalf JA, et al. Evaluation of 377 the Performance of the Sysmex XT-2000i Hematology Analyzer With Whole Bloods 378 Stored at Room Temperature. Lab Med [Internet]. 2009 Dec [cited 2024 Jan 379 30];40(12):709. Available from: /pmc/articles/PMC2860627/
- 381 17. Bah M, Verhoef H, Okoh E, Prentice A, Cerami C. Haem iron versus ferrous iron 382 salts to treat iron deeciency anaemia in Gambian children: protocol for randomised 383 controlled trial {1}. 2024;
- 385 18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research 386 Electronic Data Capture (REDCap) - A metadata-driven methodology and workflow 387 process for providing translational research informatics support. J Biomed Inform 388 [Internet]. 2009 Apr [cited 2024 Mar 8];42(2):377. Available from: 389 /pmc/articles/PMC2700030/
- 391 19. HemoCue. Hb 301 System | Robust Blood Testing Set | HemoCue America 392 [Internet]. 2023 [cited 2023 Dec 14]. Available from: https://www.hemocue.us/hb-393 301/
- 395 20. WestgardQC. CLIA Requirements for Analytical Quality Westgard [Internet]. 2023 396 [cited 2024 Apr 16]. Available from: https://www.westgard.com/clia-a-quality/quality-397 requirements/125-clia.html
- 399 21. Fothergill A, Crider KS, Johnson CB, Raj MP, Guetterman HM, Bose B, et al. 400 Comparison of Anemia Screening Methods Using Paired Venous Samples in 401 Women of Reproductive Age in Southern India. J Nutr [Internet]. 2022 Dec 1 [cited 402 2024 Apr 16];152(12):2978. Available from: /pmc/articles/PMC9840000/
- 404 22. Hinnouho GM, Barffour MA, Wessells KR, Brown KH, Kounnavong S, 405 Chanhthavong B, et al. Comparison of haemoglobin assessments by HemoCue and 406 two automated haematology analysers in young Laotian children. J Clin Pathol

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.05.24313093;](https://doi.org/10.1101/2024.09.05.24313093) this version posted September 6, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.05.24313093;](https://doi.org/10.1101/2024.09.05.24313093) this version posted September 6, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- 460 **Table 1: P**resents the absolute and proportional bias with their corresponding 95%
- 461 confidence intervals, for haemoglobin concentration measurements obtained by
- 462 HemoCue-301. The absolute bias is expressed in grams per decilitre (g/dL), and the
- 463 proportional bias is presented as a percentage (%).

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

471 **Figure 1 Comparison of haemoglobin concentrations measured by HemoCue 301 vs** 472 **Sysmex XN-1500.**

- 473 HemoCue data were truncated at haemoglobin concentration <11.0g/dL (see text)
- 474 **Panel A**:The black line represents the Passing-Bablok equation:
- 475 = Intercept (4.32) + $Slope(0.60) \times Sysmex Haemoglobin$; the red dashed line
- 476 represents the identity line; the grey shade area indicates the 95% confidence band.
- 477 **Panel B**: The black line represents the Passing-Bablok equation: Absolute Bias $=$
- 478 HemoCue method(Intercept + $Slope \times Sysmex$ Haemoglobin) –
- 479 (Sysmex Haemogloin(reference method)); the red line signifies the zero bias, the blue
- 480 dashed line represent ±7% acceptable difference and the grey shade indicates the 95% 481 confidence interval.
- 482 **Panel C:** The black line represents the Passing-Bablok equation: *Proportional bias(Xc)* =
- 483 $\frac{Intercept + (Slope 1) \times Xc}{Xc}$ where the Intercept represents the constant bias at zero Sysmex
- 484 (reference method), Slope reflects the proportional bias, and Xc denotes the specific
- 485 Sysmex value for assessing percentage bias, the numerator combines the constant and
- 486 proportional biases and divide it by Xc to normalizes the bias; The red dashed line signifies
- 487 the zero bias, the blue dashed line represent ±7% acceptable difference, and the grey
- 488 shade indicates the 95% confidence interval.
- 489

Comparison of haemoglobin concentration measurements using HemoCue-301 and

 $\mathbf 1$

- 16 Table 1: Presents the absolute and proportional bias with their corresponding 95%
- 17 confidence intervals, for haemoglobin concentration measurements obtained by
- HemoCue-301. The absolute bias is expressed in grams per decilitre (g/dL), and the 18
- 19 proportional bias is presented as a percentage (%).

20

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.05.24313093;](https://doi.org/10.1101/2024.09.05.24313093) this version posted September 6, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

- 26 HemoCue data were truncated at haemoglobin concentration <11.0g/dL (see text)
- Panel A: The black line represents the Passing-Bablok equation: HaemoCue Haemoglobin 27
- 28 = Intercept (4.32) + Slope(0.60) \times Sysmex Haemoglobin; the red dashed line
- represents the identity line; the grey shade area indicates the 95% confidence band. 29
- Panel B: The black line represents the Passing-Bablok equation: Absolute Bias = 30
- 31 $HemoCue method[Intercept + Slope \times Sysmex Haemoglobin]$ -
- 32 $(Sysmex Haemoglobin(reference method))$; the red line signifies the zero bias, the blue
- dashed line represent ±7% acceptable difference and the grey shade indicates the 95% 33 34 confidence interval.
- **Panel C:** The black line represents the Passing-Bablok equation: *Proportional bias(Xc)* = 35
- $\frac{Intercept + (Slope 1) \times Xc}{Xc}$ where the Intercept represents the constant bias at zero Sysmex 36
- (reference method), Slope reflects the proportional bias, and Xc denotes the specific 37
- 38 Sysmex value for assessing percentage bias, the numerator combines the constant and
- 39 proportional biases and divide it by Xc to normalizes the bias; The red dashed line signifies
- 40 the zero bias, the blue dashed line represent ±7% acceptable difference, and the grey 41 shade indicates the 95% confidence interval.
- 42
- 43